Evolent Health, Inc (NYSE:EVH) President Seth Blackley sold 15,000 shares of the company’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $25.22, for a total transaction of $378,300.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Seth Blackley also recently made the following trade(s):

  • On Monday, May 15th, Seth Blackley sold 15,000 shares of Evolent Health stock. The stock was sold at an average price of $25.00, for a total transaction of $375,000.00.
  • On Monday, April 17th, Seth Blackley sold 15,000 shares of Evolent Health stock. The stock was sold at an average price of $21.48, for a total transaction of $322,200.00.
  • On Thursday, March 30th, Seth Blackley sold 15,000 shares of Evolent Health stock. The stock was sold at an average price of $21.19, for a total transaction of $317,850.00.

Shares of Evolent Health, Inc (NYSE:EVH) remained flat at $26.40 during trading on Monday. 829,766 shares of the stock traded hands. The firm’s market cap is $1.52 billion. The company’s 50-day moving average is $24.43 and its 200-day moving average is $20.48. Evolent Health, Inc has a 52 week low of $14.50 and a 52 week high of $27.50.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Tuesday, May 9th. The technology company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by $0.11. Evolent Health had a negative net margin of 17.69% and a negative return on equity of 7.06%. The company had revenue of $106.80 million for the quarter, compared to the consensus estimate of $104.38 million. During the same quarter in the prior year, the firm earned ($0.16) earnings per share. Evolent Health’s revenue for the quarter was up 116.2% compared to the same quarter last year. Equities research analysts anticipate that Evolent Health, Inc will post ($0.41) EPS for the current year.

Insider Buying and Selling by Quarter for Evolent Health (NYSE:EVH)

COPYRIGHT VIOLATION NOTICE: “Seth Blackley Sells 15,000 Shares of Evolent Health, Inc (EVH) Stock” was first published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/06/19/seth-blackley-sells-15000-shares-of-evolent-health-inc-evh-stock.html.

Several large investors have recently modified their holdings of the stock. Putnam Investments LLC bought a new stake in shares of Evolent Health during the fourth quarter worth $2,536,000. AQR Capital Management LLC boosted its stake in shares of Evolent Health by 134.7% in the fourth quarter. AQR Capital Management LLC now owns 25,657 shares of the technology company’s stock worth $380,000 after buying an additional 14,723 shares in the last quarter. Perceptive Advisors LLC bought a new stake in shares of Evolent Health during the fourth quarter worth $4,555,000. Alyeska Investment Group L.P. boosted its stake in shares of Evolent Health by 29.3% in the fourth quarter. Alyeska Investment Group L.P. now owns 650,000 shares of the technology company’s stock worth $9,620,000 after buying an additional 147,400 shares in the last quarter. Finally, Two Sigma Investments LP boosted its stake in shares of Evolent Health by 84.4% in the fourth quarter. Two Sigma Investments LP now owns 298,061 shares of the technology company’s stock worth $4,411,000 after buying an additional 136,407 shares in the last quarter. Institutional investors and hedge funds own 73.46% of the company’s stock.

EVH has been the subject of a number of analyst reports. Robert W. Baird initiated coverage on shares of Evolent Health in a research report on Thursday, June 1st. They set an “outperform” rating and a $30.00 price objective for the company. CIBC initiated coverage on shares of Evolent Health in a research report on Tuesday, March 14th. They set an “outperform” rating for the company. Zacks Investment Research downgraded shares of Evolent Health from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Cantor Fitzgerald restated a “buy” rating and set a $26.00 price objective on shares of Evolent Health in a research report on Wednesday, March 1st. Finally, Goldman Sachs Group, Inc. (The) upgraded shares of Evolent Health from a “buy” rating to a “conviction-buy” rating and set a $30.00 price objective for the company in a research report on Wednesday, March 8th. One research analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $29.20.

Evolent Health Company Profile

Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.

Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.